liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer
Karolinska Institute, Sweden .
Karolinska Institute, Sweden .
Karolinska Institute, Sweden .
Karolinska Institute, Sweden .
Show others and affiliations
2013 (English)In: Nature Communications, ISSN 2041-1723, E-ISSN 2041-1723, Vol. 4, no 3175Article in journal (Refereed) Published
Abstract [en]

About one-third of oestrogen receptor alpha-positive breast cancer patients treated with tamoxifen relapse. Here we identify the nuclear receptor retinoic acid receptor alpha as a marker of tamoxifen resistance. Using quantitative mass spectrometry-based proteomics, we show that retinoic acid receptor alpha protein networks and levels differ in a tamoxifen-sensitive (MCF7) and a tamoxifen-resistant (LCC2) cell line. High intratumoural retinoic acid receptor alpha protein levels also correlate with reduced relapse-free survival in oestrogen receptor alpha-positive breast cancer patients treated with adjuvant tamoxifen solely. A similar retinoic acid receptor alpha expression pattern is seen in a comparable independent patient cohort. An oestrogen receptor alpha and retinoic acid receptor alpha ligand screening reveals that tamoxifen-resistant LCC2 cells have increased sensitivity to retinoic acid receptor alpha ligands and are less sensitive to oestrogen receptor alpha ligands compared with MCF7 cells. Our data indicate that retinoic acid receptor alpha may be a novel therapeutic target and a predictive factor for oestrogen receptor alpha-positive breast cancer patients treated with adjuvant tamoxifen.

Place, publisher, year, edition, pages
Nature Publishing Group: Nature Communications , 2013. Vol. 4, no 3175
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-103410DOI: 10.1038/ncomms3175ISI: 000323716600011OAI: oai:DiVA.org:liu-103410DiVA: diva2:689061
Available from: 2014-01-20 Created: 2014-01-20 Last updated: 2017-12-06

Open Access in DiVA

fulltext(1569 kB)176 downloads
File information
File name FULLTEXT01.pdfFile size 1569 kBChecksum SHA-512
b7f3c0a06a934900157ab88e0321d667ce9540f20127650702facde78138a9a8663c26f9979458c05fee98a3357ae5c78ab5b09adc791c3f4a72c1d3b203fa9a
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Authority records BETA

Stål, Olle

Search in DiVA

By author/editor
Stål, Olle
By organisation
Division of Clinical SciencesFaculty of Health SciencesDepartment of Oncology
In the same journal
Nature Communications
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 176 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 79 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf